These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 7930627)

  • 1. A humanized, bispecific immunoadhesin-antibody that retargets CD3+ effectors to kill HIV-1-infected cells.
    Chamow SM; Zhang DZ; Tan XY; Mhatre SM; Marsters SA; Peers DH; Byrn RA; Ashkenazi A; Junghans RP
    J Immunol; 1994 Nov; 153(9):4268-80. PubMed ID: 7930627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A humanized, bispecific immunoadhesin-antibody that retargets CD3+ effectors to kill HIV-1-infected cells.
    Chamow SM; Zhang D; Tan XY; Mhatre SM; Marsters SA; Peers DH; Byrn RA; Ashkenazi A; Junghans RP
    J Hematother; 1995 Oct; 4(5):439-46. PubMed ID: 8581382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Janusin: new molecular design for bispecific reagents.
    Traunecker A; Lanzavecchia A; Karjalainen K
    Int J Cancer Suppl; 1992; 7():51-2. PubMed ID: 1428404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biologic properties of a bispecific single-chain antibody directed against 17-1A (EpCAM) and CD3: tumor cell-dependent T cell stimulation and cytotoxic activity.
    Mack M; Gruber R; Schmidt S; Riethmüller G; Kufer P
    J Immunol; 1997 Apr; 158(8):3965-70. PubMed ID: 9103467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lysis of cells infected with HIV-1 by human lymphocytes targeted with monoclonal antibody heteroconjugates.
    Zarling JM; Moran PA; Grosmaire LS; McClure J; Shriver K; Ledbetter JA
    J Immunol; 1988 Apr; 140(8):2609-13. PubMed ID: 2965725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Visualization of effective tumor targeting by CD8+ natural killer T cells redirected with bispecific antibody F(ab')(2)HER2xCD3.
    Scheffold C; Kornacker M; Scheffold YC; Contag CH; Negrin RS
    Cancer Res; 2002 Oct; 62(20):5785-91. PubMed ID: 12384539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GP120 specific cellular cytotoxicity in HIV-1 seropositive individuals. Evidence for circulating CD16+ effector cells armed in vivo with cytophilic antibody.
    Tyler DS; Nastala CL; Stanley SD; Matthews TJ; Lyerly HK; Bolognesi DP; Weinhold KJ
    J Immunol; 1989 Feb; 142(4):1177-82. PubMed ID: 2536767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cutting edge: RANTES regulates Fas ligand expression and killing by HIV-specific CD8 cytotoxic T cells.
    Hadida F; Vieillard V; Mollet L; Clark-Lewis I; Baggiolini M; Debré P
    J Immunol; 1999 Aug; 163(3):1105-9. PubMed ID: 10415001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Fc gamma receptor mediated T-cell activation by two purified CD3 x CD19 bispecific monoclonal antibodies with hybrid Fc domains.
    Haagen IA; Geerars AJ; Bast EJ; de Gast GC; van de Winkel JG; de Lau WB
    Ther Immunol; 1994 Oct; 1(5):279-87. PubMed ID: 7584502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diabody-based recombinant formats of humanized IgG-like bispecific antibody with effective retargeting of lymphocytes to tumor cells.
    Asano R; Kawaguchi H; Watanabe Y; Nakanishi T; Umetsu M; Hayashi H; Katayose Y; Unno M; Kudo T; Kumagai I
    J Immunother; 2008 Oct; 31(8):752-61. PubMed ID: 18779744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bispecific anti-CD22/anti-CD3-ricin A chain immunotoxin is cytotoxic to Daudi lymphoma cells but not T cells in vitro and shows both A-chain-mediated and LAK-T-mediated killing.
    Shen GL; Li JL; Vitetta ES
    J Immunol; 1994 Mar; 152(5):2368-76. PubMed ID: 8133047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimizing anti-CD3 affinity for effective T cell targeting against tumor cells.
    Bortoletto N; Scotet E; Myamoto Y; D'Oro U; Lanzavecchia A
    Eur J Immunol; 2002 Nov; 32(11):3102-7. PubMed ID: 12385030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bispecific antibodies increase T-cell stimulatory capacity in vitro of human autologous virus-modified tumor vaccine.
    Haas C; Strauss G; Moldenhauer G; Iorio RM; Schirrmacher V
    Clin Cancer Res; 1998 Mar; 4(3):721-30. PubMed ID: 9533542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of T cell activation in anti-CD3 x antitumor bispecific antibody therapy.
    Weiner GJ; Kostelny SA; Hillstrom JR; Cole MS; Link BK; Wang SL; Tso JY
    J Immunol; 1994 Mar; 152(5):2385-92. PubMed ID: 8133049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD44 is a cytotoxic triggering molecule in human peripheral blood NK cells.
    Sconocchia G; Titus JA; Segal DM
    J Immunol; 1994 Dec; 153(12):5473-81. PubMed ID: 7527443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inefficient cytotoxic T lymphocyte-mediated killing of HIV-1-infected cells in vivo.
    Asquith B; Edwards CT; Lipsitch M; McLean AR
    PLoS Biol; 2006 Apr; 4(4):e90. PubMed ID: 16515366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concomitant killing in vitro of both gp120-coated CD4+ peripheral T lymphocytes and natural killer cells in the antibody-dependent cellular cytotoxicity (ADCC) system.
    Jewett A; Cavalcanti M; Giorgi J; Bonavida B
    J Immunol; 1997 Jun; 158(11):5492-500. PubMed ID: 9164972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carcinoembryonic antigen (CEA)-specific T-cell activation in colon carcinoma induced by anti-CD3 x anti-CEA bispecific diabodies and B7 x anti-CEA bispecific fusion proteins.
    Holliger P; Manzke O; Span M; Hawkins R; Fleischmann B; Qinghua L; Wolf J; Diehl V; Cochet O; Winter G; Bohlen H
    Cancer Res; 1999 Jun; 59(12):2909-16. PubMed ID: 10383154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective targeting and potent control of tumor growth using an EphA2/CD3-Bispecific single-chain antibody construct.
    Hammond SA; Lutterbuese R; Roff S; Lutterbuese P; Schlereth B; Bruckheimer E; Kinch MS; Coats S; Baeuerle PA; Kufer P; Kiener PA
    Cancer Res; 2007 Apr; 67(8):3927-35. PubMed ID: 17440108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD3-CD28 costimulation as a means to avoiding T cell preactivation in bispecific monoclonal antibody-based treatment of ovarian carcinoma.
    Mazzoni A; Mezzanzanica D; Jung G; Wolf H; Colnaghi MI; Canevari S
    Cancer Res; 1996 Dec; 56(23):5443-9. PubMed ID: 8968099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.